media – Page 14 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Johnson & Johnson projects its revenue will reach $100 billion by 2026.

Today, Johnson & Johnson released its 2025 financial results. Full-year revenue reached $94.2 billion, a 6.0% increase year-over-year ; net income reached $26.8 billion, with diluted earnings per share (EPS) of $11.03, a 90.5% increase year-over-year; adjusted EPS was $10.79, an 8.1% increase year-over-year. Johnson & Johnson Chairman and CEO Joaquin Duato stated that 2025 will be a pivotal year for the company, marking the beginning of a new era of accelerated growth. The company projects its sales will reach $100 billion by 2026 . In 2022, Pfizer became the first biopharmaceutical company to reach $100 billion in annual revenue. However, since COVID-19 products accounted for more than half of its sales, its revenue surge lasted only one year. Four years later, Johnson & Johnson is also about to reach the $100 billion milestone, and this achievement seems to be more sustainable. Johnson & Johnson’s current business consists of two ...
- Source: drugdu
- 83
- January 26, 2026
Eli Lilly’s “miracle weight-loss drug” targets a new trillion-dollar market; is it about to revolutionize the liver disease treatment landscape?

Recently, according to the CDE (Center for Drug Evaluation) website, Eli Lilly’s GIP/GLP-1 dual receptor agonist, “Telborpeptide Injection,” is proposed for inclusion in the Breakthrough Therapy designation for the treatment of metabolic-associated fatty liver disease (MASH). This marks the fourth major market for Telborpeptide in China. Previously, it has been approved in China for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea. This proposed inclusion in the Breakthrough Therapy designation signifies its significant advantages in treating MASH, and its market launch is expected to be significantly accelerated. MASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, leading to inflammation and fibrosis. Approximately one-third of overweight or obese individuals may have MASH. However, the path to drug development for MASH has been exceptionally arduous, with a complex pathogenesis that has caused numerous pharmaceutical giants to fail over the past few decades, ...
- Source: drugdu
- 118
- January 26, 2026
Xijing Zhiyuan Secures Over 200 Million Yuan in Series B Funding to Accelerate Clinical Development of Solid Tumor TCR-T Therapies

Recently, Xijing Zhiyuan Biotech (Suzhou) Co., Ltd. (hereinafter referred to as “Xijing Zhiyuan” or the “Company”), an innovative enterprise focused on the development of TCR-T immune cell therapy drugs for solid tumors, announced the completion of a Series B financing round exceeding RMB 200 million. The round was co-led by Apricot Capital and a well-known industry fund, with participation from Delian Capital, Yuanhe Holdings, and Suzhou Angel Mother Fund, as well as continued strong support from existing shareholders Ton Hi Capital and GEM Co., Ltd. Halo Capital served as the exclusive financial advisor for this round of financing. Founded in 2020 and headquartered in Suzhou, Xijing Zhiyuan is an innovative enterprise dedicated to the development of TCR-T immune cell therapy drugs for solid tumors. The Company has independently developed a high-throughput, high-sensitivity target antigen–natural TCR discovery platform. By combining computational and experimental validation with iterative feedback, it efficiently screens for ...
- Source: drugdu
- 77
- January 26, 2026
India’s Generic Giant Secures Semaglutide Nod; Local GLP-1 Market Hits $1.2 Billion

As the March 2026 patent cliff approaches, the fiercest battle in the global GLP-1 market is quietly taking shape in India. Over the past three years, few sectors in the global pharmaceutical industry have sustained such wealth myths as GLP-1 weight-loss and diabetes drugs; from Europe and the U.S. to Asia, semaglutide has rapidly evolved from a prescription medicine into a social issue, while beneath this wave India—known as the “world’s pharmacy”—is brewing a systemic shock powerful enough to rewrite the pricing structure. According to the latest court developments, with Novo Nordisk’s core patents entering their final countdown, major Indian generic drugmakers are fully in place, and a multi-billion-dollar battle for dominance in the GLP-1 market is waiting only for the starting gun. All attention is focused on a clear date: March 20, 2026, which is when a key semaglutide patent expires in India and is also seen as the ...
- Source: drugdu
- 91
- January 26, 2026
【EXPERT Q&A】What certifications are required for the export of medical devices to Brazil?

Drugdu.com expert’s response: Medical devices exported to Brazil must obtain ANVISA certification (core market access certification), INMETRO certification (for specific high-risk products), quality management system certification (e.g., ISO 13485), and ensure labeling and instruction compliance. Certain products may also require ANATEL certification (for wireless communication functionality) or MDSAP audit (as an alternative to ANVISA review). Below is a detailed explanation: I. ANVISA Certification: Core Market Access Threshold Scope of Application: All medical devices imported or distributed in Brazil, regardless of risk classification, must obtain ANVISA certification. Key Requirements: Mandatory Registration: Applications must be submitted online through ANVISA’s SGP system, covering all classified medical devices. Risk-Based Classification: Devices are categorized into four classes (Class I: low risk; Class II: moderate risk; Class III: high risk; Class IV: extremely high risk), with varying documentation requirements: Class I: Basic information and technical documentation; simpler review process. Class II: Detailed technical documentation; may require performance test reports. Class III: Complete clinical ...
- Source: drugdu
- 89
- January 26, 2026
RiboBio’s ApoC3-Targeting siRNA Drug RBD5044 Granted Implicit Approval for Phase II Clinical Trials in China

Suzhou RiboLife Sciences Co., Ltd. (RiboLife Sciences, Hong Kong Stock Exchange: 06938) announced that RBD5044, a novel siRNA drug targeting ApoC3 independently developed by the Company, received Implicit Approval for Phase II Clinical Trials from the National Medical Products Administration (NMPA) on January 22, 2026. RBD5044 is a small nucleic acid drug for the treatment of hypertriglyceridemia developed based on the RiboGalSTAR™ liver‑targeting technology platform, and is also the second ApoC3‑targeting siRNA globally to enter clinical development. Available Phase I clinical data show that a single administration achieved significant inhibition of apolipoprotein C3 (ApoC3) by up to 84%, accompanied by a reduction in triglyceride (TG) levels of up to 70%. Furthermore, during the 6‑month follow‑up period, subjects’ TG levels remained stably below 50% of baseline, and overall lipid profiles were comprehensively improved. Meanwhile, RBD5044 demonstrated favorable tolerability, with no dose‑dependent adverse events or elevated liver enzymes observed even at ...
- Source: drugdu
- 76
- January 23, 2026
A new generation of ophthalmic dual antibodies challenges Roche’s dominant position.

Ollin recently released early data on its VEGF/Ang2 bispecific antibody OLN324 against Roche’s blockbuster product Vabysmo. The results showed that nearly 90% of patients with diabetic macular edema (DME) achieved lesion resolution within 12 weeks , while Roche’s Vabysmo only achieved 57% in the same metric. This means that the drug has the potential to cause lesion reversal and revolutionize the treatment of retinal diseases. 01 Head-to-head challenge against Roche’s pharmaceutical giant head-to-head phase 1b clinical trial conducted in multiple centers in the United States . It enrolled more than 160 patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME) and compared the efficacy and safety of IBI324 with Vabysmo (faricimab). Results showed that at week 12, nearly 90% of patients with DME treated with OLN324 4 mg achieved DME elimination (defined as central retinal thickness CST < 325 μm), compared to 57% in the faricimab group ...
- Source: drugdu
- 114
- January 23, 2026
Leading CRO company sees net profit surge 1468%

Today (January 21), Joinn Laboratories, a leading preclinical CRO, released its 2025 annual performance forecast, projecting a net profit excluding non-recurring items of 250-370 million yuan, representing a year-on-year increase of approximately 945%-1468% . The performance curve of Joinn Laboratories has been nothing short of dramatic. In 2022, the company reached a historical peak with a net profit of 1.074 billion yuan, but then its fortunes plummeted in the following two years —net profit halved to 397 million yuan in 2023, and then plunged 81% to 74.08 million yuan in 2024. The turning point came in 2025, when the company’s net profit attributable to the parent company reached 80.71 million yuan in the first three quarters, achieving a turnaround from loss to profit compared to the same period last year . It is worth noting that Zhaoyan New Drug’s operating revenue will continue to decline in 2025, with an estimated ...
- Source: drugdu
- 77
- January 23, 2026
Robotic diagnosis and treatment is reaching a turning point towards widespread adoption.

In today’s rapidly developing technological landscape, robots are integrating into the field of surgical diagnosis and treatment at an unprecedented pace, bringing patients a more precise and safer medical experience and providing doctors with stronger technical support. However, the lack of unified standards for the pricing mechanisms of innovative medical services has, to some extent, affected their clinical promotion and sustainable development. On December 5, 2025, the National Healthcare Security Administration issued the “Guidelines for the Establishment of Pricing Items for Surgical and Treatment Assistance Medical Services (Draft for Comments)” to provincial healthcare security bureaus for internal feedback within the healthcare security system. This marks the first time that the pricing mechanisms for innovative medical services such as surgical robots have been systematically standardized at the national level. Robotic diagnosis and treatment has become a powerful tool for solving clinical pain points. “Early diagnosis of lung cancer has always been ...
- Source: drugdu
- 75
- January 23, 2026
The Phase 1 clinical trial showed amazing results, causing the stock price to surge by 166%.

Corvus Pharmaceuticals recently released updated Phase 1 clinical data on the ITK inhibitor Soquelitinib for the treatment of atopic dermatitis. Corvus Pharmaceuticals’ stock price surged 166% that day , reaching a market capitalization of $1.6 billion. Soquelitinib blocks the TCR pathway, increasing Th1 while downregulating Th2 and Th17, the latter two playing important roles in autoimmune diseases. Soquelitinib is a selective ITK inhibitor and the world’s first ITK inhibitor, with potential indications being explored for PTCL, AD, and other indications. Atopic dermatitis still presents significant unmet clinical needs, with 50% of patients failing biologic therapy. Soquelitinib has updated the data from Phase 1 cohort 4 of its clinical trial, with the clinical protocol design as follows. The patient’s baseline information is as follows. The previously released efficacy data for cohorts 1-3 after 4 weeks of treatment are as follows. In cohort 3, treatment was discontinued after 4 weeks, and the ...
- Source: drugdu
- 84
- January 23, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.